A Prospective Study of Risk Factors for Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

Purpose: The study investigated the clinical risk factors of peripheral neuropathy induced by docetaxel and albumin-bound paclitaxel (AP) in breast cancer patients. Methods: : A prospective observational study was performed in 268 patients from March 2019 to December 2020, related information of patients can be obtained by querying the electronic system, consulting the patient and evaluating the scale, neuropathic symptoms are followed up from the beginning to three months after taxane drug chemotherapy. Univariate and multivariate analysis were used to find the risk factors of overall and severe taxane-induced peripheral neuropathy (TIPN). Results: : The cumulative dose ( OR =3.533, 95% CI 1.797～6.944，p<0.001) , body mass index (BMI)( OR =2.926，95% CI 1.621～5.281，p<0.001), body surface area(BSA) (OR=1.724，95% CI: 1.011～2.941, p=0.045) , hypocalcemia (OR = 4.899, 95% CI: 1.518 ~ 15.811, P = 0.008) all increased the risk of TIPN, only cumulative dose (OR=2.577，95% CI: 1.161～5.719，p=0.020) and BSA (OR=2.040，95% CI: 1.073～3.877，p=0.030) were independent risk factors for severe TIPN. Conclusion: Cumulative dose, BMI, BSA, and hypocalcemia are risk factors for overall TIPN, while cumulative dose and BSA are risk factors for severe TIPN. Breast cancer patients, those with high BMI and large BSA, hypocalcemia and large cumulative dose can be closely followed by TIPN, preventive intervention measures actively carried out.